The abstracts selected for publication from this year’s ASCO Annual Meeting include 258 (12%) abstracts from Memorial Sloan Kettering out of a total of 2,100 abstracts. The top 7 MSK authors all published 10 or more abstracts: J. D. Wolchok (18), N. A. Rizvi (14), C. A. Hudis (13), M. G. Kris (12), R. J. Motzer (12), C. S. Sima (11), and J. Baselga (10). The top three categories of articles (as determined by ASCO) were Gastrointestinal (Noncolorectal) Cancer (22), Lung Cancer-Non-Small Cell Metastatic (21), and Genitourinary (Prostate) Cancer (20). The abstracts included two on the historic IBM Watson Oncology application being implemented at MSK.


CA, Alliance for Clinical Trials in Oncology. Gene expression signatures in pre- and post-therapy (Rx) specimens from CALGB 40601 (Alliance), a neoadjuvant phase III trial of weekly paclitaxel and trastuzumab with or without lapatinib for HER2-positive breast cancer (BrCa). ASCO Meeting Abstracts. 2014;32(15_suppl):506. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/506.


44. Davids MS, Seymour JF, Gerecitano JF, Kahl BS, Pagel JM, Wierda WG, Anderson MA, Rudersdorf N, Gressick LA, Montalvo NP, Yang J, Zhu M, Dunbar M, Cerri E, Enschede SH, Humerrickhouse R, Roberts AW. Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at
http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8522.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5008.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10508.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2547.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/1098.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10527.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10022.


72. Fury MG, Xiao H, Baxi SS, Sherman EJ, Smith-Marrone S, Ho AL, Sima CS, Nwankwo OG, Haque S, Katabi N, Pfister DG. A phase II trial of temsirolimus plus low-
http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/6019.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4512.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS3116.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8020.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS8120.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8024.


85. Gucalp A, Krasne MD, Jakate KA, Drill EN, Wen YH, Akram M, Ho AY, Gupta GP, Brogi E, Hudis CA, Traina TA. CK14, FOXA1, and androgen receptor (AR)
http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/1126.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS1615.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/5002.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3000.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e16045.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4504.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e15125.


98. Ho TH, Choueiri TK, D'Amelio A, Hsieh J, De Souza PL, Deen KC, Langmuir PB, Liu Y, Motzer RJ. The effect of SETD2 mutation (mts) on histone 3 lysine 36 trimethylation (H3K36me3) and correlation with clinical outcome in patients (pts) with metastatic clear cell renal cell carcinoma (ccRCC) enrolled in COMPARZ. ASCO


150. Momtaz P, Gaskell AA, Merghoub T, Viale A, Chapman PB. Correlation of tumor-derived circulating cell free DNA (cfDNA) measured by digital PCR (DigPCR) with tumor burden measured radiographically in patients (pts) with BRAFV600Emutated melanoma (mel) treated with RAF inhibitor (RAFi) and/or ipilimumab (Ipi). ASCO Meeting Abstracts. 2014;32(15_suppl):9085. http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9085.


152. Morikawa A, Jhaveri KL, Patil S, Chen M, McDonnell E, Neville DA, Mak FM, Gansukh B, John HL, Holodny A, Schoder H, Beal K, Seidman AD. A phase I trial of sorafenib with whole brain radiotherapy (WBRT) in breast cancer patients with brain metastases and a correlative study of FLT-PET brain imaging to evaluate treatment...


http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2071.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4023.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2558.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3021.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8035.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2522.

172. Park JH, Riviere I, Wang X, Bartido S, Sadelain M, Brentjens RJ. Phase I trial of autologous CD19-targeted CAR-modified t cells as consolidation after purine analog-based first-line therapy in patients with previously untreated CLL. ASCO Meeting
http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9629.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e15233.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e16061.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/7514.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS8622.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/LBA4.


199. Rizvi NA, Garon EB, Patnaik A, Gandhi L, Leighl NB, Balmanoukian AS, Goldman JW, Eder JP, Johnson E, Blumenschein GR, Gubens MA, Papadopoulos KP,
http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/8007.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4510.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/645.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3022.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4137.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e15243.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS7123.


http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/TPS3115.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e20683.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/7015.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/2605.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e17585.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/e17572.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10521.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/10582.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3003.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/3538.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/4514.

http://meeting.ascopubs.org/cgi/content/abstract/32/15_suppl/9009.


